Glycogen synthase kinase‐3β (GSK‐3β) is a multifunctional serine‐threonine kinase, which is expressesed in all eukaryotic cells. Many diseases, such as metabolic diseases, cancer, digestive diseases and lung diseases, have been confirmed to be associated with the changes of expression level of GSK‐3β. At present, studies have found that it is also involved in the development of nervous system diseases such as traumatic brain injury, Alzheimer's psychosis, etc. This article summarizes the regulatory mechanism of GSK‐3β in the development of nerve diseases and intends to clarify the mechanisms of nervous system disease to guide its application in future clinic trial.